Drugs / Prontosan
last change Apr 2026 re-read 2 minutes ago

Prontosan

Other / unclassified

Developed for
decubitus ulcer · skin infection · chronic ulcer of skin
Investigated by
FISABIO Foundation · Georgetown University

Trials 2 · a red edge is where a trial was stopped

20142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 01 trial
Phase 0 NCT07391748 Jan → Apr 2026 overdue decubitus ulcer FISABIO Foundation Not yet recruiting No outcome recorded
Phase 41 trial
Phase 4 NCT01939145 Sep 2013 → Jul 2014 skin infection Georgetown University Completed No outcome recorded
Also used as a comparator or background therapy in 2 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 31 trial
Phase 3 NCT06297967 Comparator Apr 2025 → Mar 2027 expected chronic ulcer of skin Consorci Sanitari de l'Alt Penedès i Garraf Recruiting No outcome recorded
Phase 41 trial
Phase 4 NCT06309368 Comparator Mar 2024 → Dec 2028 expected large intestine disorder University of Nevada, Las Vegas Recruiting No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 4 sources stand behind the page.

FieldValueCited text
Known as Prontosan “The intervention consists of the topical application of a gel containing polyhexanide and biguanide (Prontosan®), either alone or in combination with a silver-containing...” NCT07391748
3

Prontosan (B Braun, Bethlehem, PA) is 0.1% polyhexanide, 0.1% betaine, sodium hydroxide, and purified water.” NCT01939145

“The incision will then be irrigated using direct stream into the wound with 350cc of Prontosan.” NCT06309368

NCT06297967

Modality Other / unclassified “0.1% betaine and 0.1 % polyhexamethylene biguanide antimicrobial solution” NCT06309368
Route Topical “This solution is an FDA approved device indicated for topical irrigation.” NCT01939145